Summary
Guardant Health, Inc. (GH) announced a significant development regarding its Shield blood test for colorectal cancer screening. On May 23, 2024, the company issued a press release detailing that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee has provided a strong recommendation for the approval of Shield. This recommendation specifically targets screening for colorectal cancer in adults aged 45 and older who are at average risk for the disease. The advisory committee's vote was overwhelmingly positive across key safety and efficacy measures. Panel members voted favorably regarding the test's safety (8-1), effectiveness (6-3), and the balance of benefits over risks (7-2). While this recommendation is a crucial step, it will be considered by the FDA as part of its ongoing premarket approval review for the Shield test. This positive advisory panel opinion signals strong potential for the Shield test to become a widely available screening option, which could significantly impact the landscape of colorectal cancer detection.
Key Highlights
- 1FDA Advisory Committee strongly recommended approval of Guardant Health's Shield blood test for colorectal cancer screening.
- 2The recommendation is for adults aged 45 and older at average risk for colorectal cancer.
- 3Panel voted favorably on safety (8-1), effectiveness (6-3), and benefit-risk profile (7-2) of the Shield test.
- 4This recommendation is a key step in the FDA's premarket approval process for the Shield test.
- 5The positive vote indicates strong confidence from the advisory committee in the test's clinical utility.
- 6Guardant Health announced this development via a press release filed as an exhibit to the 8-K.